Europe Whole Exome Sequencing Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144140
- Pages: 225
-
Format:
Short Description
Europe Whole Exome Sequencing Market, Component (Whole Exome Sequencing, Second-Generation Sequencing, Third-Generation Sequencing), Product And Services (Systems, Kits, Services), Application (Diagnostics, Drug Discovery And Development, Personalized Medicine, Agriculture & Animal Research, Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, Others), Distribution Channel (Direct Trade, Retail Sales, Others). Industry Trends and Forecast to 2029.
Market Definition:
Whole exome sequencing is a genomic testing method available to physicians and patients indicated for unifying diagnosis of multiple medical conditions at a time. This method is primarily used for sequencing of protein-coding regions of an individuals genome and related sequences. The human exome which represents less than 2% of the genome consists of nearly 85% of known disease related variants which makes this method cost-effective alternative to whole exome sequencing.
Exome sequencing is used across a wide range of applications, including cancer studies, population genetics, and genetic disease. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.
Market Segmentation:
Europe whole exome sequencing market is categorized into five notable segments which are based on component, product and service, application, end user and distribution channel. In 2022, second generation sequencing segment is expected to dominate the market due to technological advancement in the whole exome sequencing and rising demand of effective disease diagnosis process.
On the basis of component, the whole exome sequencing market is segmented into second generation sequencing and third-generation sequencing.
On the basis of product and service, the whole exome sequencing market is segmented into systems, kits and services.
On the basis of application, the whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
On the basis of end user, the whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
On the basis of distribution channel, the whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.
Market Players
The key market players for the Europe whole exome sequencing market are listed below:
Beckman Coulter, Inc.
BIONEER CORPORATION
Eurofins Scientific
ExoDx (a part of Bio-Techne)
FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd)
QIAGEN
GeneFirst Limited
CeGaT GmbH
Illumina, Inc.
Meridian
Merck KGaA
SOPHiA GENETICS
CD Genomics
Twist Bioscience
Thermo Fisher Scientific Inc.
PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
GeneDx, LLC
Integrated DNA Technologies, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF EUROPE WHOLE EXOME SEQUENCING (WES) MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 PRODUCT TYPE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
4.1 PORTERS FIVE FORCES 58
4.2 PESTEL ANALYSIS 59
4.3 INDUSTRIAL INSIGHTS: 60
4.4 CONCLUSION 61
5 EUROPE WHOLE EXOME SEQUENCING MARKET: REGULATIONS 62
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 66
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 66
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 66
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 67
6.2 RESTRAINTS 68
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 68
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 68
6.3 OPPORTUNITIES 69
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 69
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 69
6.4 CHALLENGES 70
6.4.1 LACK OF SKILLED PROFESSIONALS 70
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 70
7 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 71
7.1 OVERVIEW 72
7.2 SECOND-GENERATION SEQUENCING 75
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 76
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 76
7.3 THIRD-GENERATION SEQUENCING 77
8 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 78
8.1 OVERVIEW 79
8.2 SYSTEMS 82
8.2.1 HISEQ SERIES 83
8.2.1.1 HISEQ 2500 83
8.2.1.2 HISEQ 1500 83
8.2.2 MISEQ SERIES 83
8.2.3 ION TORRENT PLATFORMS 84
8.2.3.1 ION PROTON 84
8.2.3.2 ION PGM 84
8.2.4 OTHERS 84
8.3 KITS 84
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 85
8.3.2 LIBRARY PREPARATION KITS 85
8.3.3 TARGET ENRICHMENT KITS 86
8.3.4 OTHERS 86
8.4 SERVICES 86
8.4.1 SEQUENCING SERVICES 87
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 87
8.4.3 OTHERS 87
9 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 DRUG DISCOVERY AND DEVELOPMENT 92
9.3 AGRICULTURE & ANIMAL RESEARCH 93
9.4 DIAGNOSTICS 93
9.5 PERSONALIZED MEDICINE 94
9.6 OTHERS 95
10 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER 96
10.1 OVERVIEW 97
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
10.3 ACADEMIC & RESEARCH INSTITUTES 101
10.4 HOSPITALS AND CLINICS 101
10.5 CLINICAL LABORATORIES 102
10.6 OTHERS 103
11 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 104
11.1 OVERVIEW 105
11.2 DIRECT TRADE 108
11.3 RETAIL SALES 108
11.4 OTHERS 110
12 EUROPE WHOLE EXOME SEQUENCING MARKET, BY REGION 111
12.1 EUROPE 112
12.1.1 GERMANY 120
12.1.2 FRANCE 124
12.1.3 U.K. 127
12.1.4 RUSSIA 131
12.1.5 ITALY 134
12.1.6 SPAIN 137
12.1.7 TURKEY 140
12.1.8 NETHERLANDS 143
12.1.9 SWITZERLAND 147
12.1.10 BELGIUM 151
12.1.11 REST OF EUROPE 155
13 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 156
13.1 COMPANY SHARE ANALYSIS: EUROPE 156
14 COMPANY PROFILE 157
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 157
14.1.1 COMPANY SNAPSHOT 157
14.1.2 REVENUE ANALYSIS 157
14.1.3 COM PANY SHARE ANALYSIS 158
14.1.4 PRODUCT PORTFOLIO 158
14.1.5 RECENT DEVELOPMENTS 158
14.2 MERCK KGAA 160
14.2.1 COMPANY SNAPSHOT 160
14.2.2 REVENUE ANALYSIS 160
14.2.3 COM PANY SHARE ANALYSIS 161
14.2.4 PRODUCT PORTFOLIO 161
14.2.5 RECENT DEVELOPMENTS 161
14.3 EXODX (A PART OF BIO-TECHNE) 162
14.3.1 COMPANY SNAPSHOT 162
14.3.2 REVENUE ANALYSIS 162
14.3.3 COM PANY SHARE ANALYSIS 163
14.3.4 PRODUCT PORTFOLIO 163
14.3.5 RECENT DEVELOPMENTS 163
14.4 THERMO FISHER SCIENTIFIC INC. 164
14.4.1 COMPANY SNAPSHOT 164
14.4.2 REVENUE ANALYSIS 164
14.4.3 COM PANY SHARE ANALYSIS 165
14.4.4 PRODUCT PORTFOLIO 165
14.4.5 RECENT DEVELOPMENTS 165
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 166
14.5.1 COMPANY SNAPSHOT 166
14.5.2 REVENUE ANALYSIS 166
14.5.3 COM PANY SHARE ANALYSIS 167
14.5.4 PRODUCT PORTFOLIO 167
14.5.5 RECENT DEVELOPMENTS 167
14.6 AZENTA US, INC. 169
14.6.1 COMPANY SNAPSHOT 169
14.6.2 PRODUCT PORTFOLIO 169
14.6.3 RECENT DEVELOPMENTS 169
14.7 BECKMAN COULTER, INC 171
14.7.1 COMPANY SNAPSHOT 171
14.7.2 REVENUE ANALYSIS 171
14.7.3 PRODUCT PORTFOLIO 172
14.7.4 RECENT DEVELOPMENTS 172
14.8 BIONEER CORPORATION 173
14.8.1 COMPANY SNAPSHOT 173
14.8.2 REVENUE ANALYSIS 173
14.8.3 PRODUCT PORTFOLIO 174
14.8.4 RECENT DEVELOPMENTS 174
14.9 CD GENOMICS 175
14.9.1 COMPANY SNAPSHOT 175
14.9.2 PRODUCT PORTFOLIO 175
14.9.3 RECENT DEVELOPMENTS 175
14.10 CEGAT GMBH 176
14.10.1 COMPANY SNAPSHOT 176
14.10.2 PRODUCT PORTFOLIO 176
14.10.3 RECENT DEVELOPMENTS 176
14.11 EUROFINS SCIENTIFIC 177
14.11.1 COMPANY SNAPSHOT 177
14.11.2 REVENUE ANALYSIS 177
14.11.3 PRODUCT PORTFOLIO 178
14.11.4 RECENT DEVELOPMENTS 178
14.12 GENEDX, LLC 179
14.12.1 COMPANY SNAPSHOT 179
14.12.2 PRODUCT PORTFOLIO 179
14.12.3 RECENT DEVELOPMENTS 179
14.13 GENEFIRST LIMITED. 181
14.13.1 COMPANY SNAPSHOT 181
14.13.2 PRODUCT PORTFOLIO 181
14.13.3 RECENT DEVELOPMENTS 181
14.14 ILLUMINA, INC 183
14.14.1 COMPANY SNAPSHOT 183
14.14.2 REVENUE ANALYSIS 183
14.14.3 PRODUCT PORTFOLIO 184
14.14.4 RECENT DEVELOPMENTS 184
14.15 INTEGRATED DNA TECHNOLOGIES, INC. 186
14.15.1 COMPANY SNAPSHOT 186
14.15.2 PRODUCT PORTFOLIO 186
14.15.3 RECENT DEVELOPMENTS 186
14.16 MERIDIAN BIOSCIENCE, INC. 188
14.16.1 COMPANY SNAPSHOT 188
14.16.2 REVENUE ANALYSIS 188
14.16.3 PRODUCT PORTFOLIO 189
14.16.4 RECENT DEVELOPMENTS 189
14.17 PSOMAGEN 190
14.17.1 COMPANY SNAPSHOT 190
14.17.2 REVENUE ANALYSIS 190
14.17.3 PRODUCT PORTFOLIO 190
14.17.4 RECENT DEVELOPMENTS 191
14.18 QIAGEN 192
14.18.1 COMPANY SNAPSHOT 192
14.18.2 REVENUE ANALYSIS 192
14.18.3 PRODUCT PORTFOLIO 193
14.18.4 RECENT DEVELOPMENTS 193
14.19 SOPHIA GENETICS 194
14.19.1 COMPANY SNAPSHOT 194
14.19.2 REVENUE ANALYSIS 194
14.19.3 PRODUCT PORTFOLIO 195
14.19.4 RECENT DEVELOPMENTS 195
14.20 TWIST BIOSCIENCE 196
14.20.1 COMPANY SNAPSHOT 196
14.20.2 REVENUE ANALYSIS 196
14.20.3 PRODUCT PORTFOLIO 197
14.20.4 RECENT DEVELOPMENTS 197
15 QUESTIONNAIRE 199
16 RELATED REPORTS 202
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
